Kestra Medical Technologies (NASDAQ:KMTS) CFO Sells $90,545.00 in Stock

Posted by Francis Steltz on Aug 3rd, 2026

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS – Get Free Report) CFO Vaseem Mahboob sold 3,980 shares of Kestra Medical Technologies stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $22.75, for a total transaction of $90,545.00. Following the transaction, the chief financial officer owned 108,099 shares in the company, valued at $2,459,252.25. This represents a 3.55% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Vaseem Mahboob also recently made the following trade(s):

On Monday, August 3rd, Vaseem Mahboob sold 5,391 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $23.80, for a total transaction of $128,305.80.
On Friday, July 31st, Vaseem Mahboob sold 8,817 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $22.61, for a total transaction of $199,352.37.

Kestra Medical Technologies Price Performance

Shares of NASDAQ KMTS traded up $1.16 during mid-day trading on Monday, reaching $23.99. The company’s stock had a trading volume of 373,728 shares, compared to its average volume of 404,856. The company has a debt-to-equity ratio of 0.16, a current ratio of 4.41 and a quick ratio of 4.41. Kestra Medical Technologies, Ltd. has a 52 week low of $14.10 and a 52 week high of $30.00. The stock has a fifty day moving average of $22.62 and a two-hundred day moving average of $22.48. The firm has a market capitalization of $1.41 billion, a PE ratio of -9.91 and a beta of 0.58.

Kestra Medical Technologies (NASDAQ:KMTS – Get Free Report) last announced its quarterly earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.08). The company had revenue of $28.64 million during the quarter. Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. As a group, sell-side analysts anticipate that Kestra Medical Technologies, Ltd. will post -2.29 EPS for the current fiscal year.

Institutional Investors Weigh In On Kestra Medical Technologies

Several institutional investors have recently made changes to their positions in KMTS. Farther Finance Advisors LLC purchased a new position in shares of Kestra Medical Technologies during the 4th quarter worth about $31,000. Russell Investments Group Ltd. lifted its stake in Kestra Medical Technologies by 43.5% in the fourth quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock worth $41,000 after purchasing an additional 474 shares during the last quarter. Daiwa Securities Group Inc. purchased a new position in shares of Kestra Medical Technologies during the fourth quarter valued at approximately $72,000. BNP Paribas Financial Markets grew its stake in shares of Kestra Medical Technologies by 148.9% during the third quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock valued at $65,000 after buying an additional 1,638 shares during the last quarter. Finally, Brown Brothers Harriman & Co. raised its holdings in shares of Kestra Medical Technologies by 26.8% in the third quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock worth $74,000 after buying an additional 656 shares during the period.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. Weiss Ratings downgraded shares of Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, July 16th. Oppenheimer started coverage on shares of Kestra Medical Technologies in a report on Tuesday, July 21st. They issued a “market perform” rating on the stock. BTIG Research increased their price target on shares of Kestra Medical Technologies from $30.00 to $32.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. Wolfe Research set a $30.00 price target on Kestra Medical Technologies in a research report on Wednesday, July 15th. Finally, The Goldman Sachs Group decreased their price objective on Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a research report on Thursday, April 9th. Three research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $27.83.

View Our Latest Research Report on KMTS

About Kestra Medical Technologies

(Get Free Report)

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.